Design Validation Hemodynamic Study of New Kendall SCD SmartFlow Compression System

Sponsor
Cardinal Health (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05945186
Collaborator
(none)
19
1
1
3
6.3

Study Details

Study Description

Brief Summary

This study is being conducted to evaluate the hemodynamic performance (i.e. flow of blood) in the legs using the new Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves.

Condition or Disease Intervention/Treatment Phase
  • Device: Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)
N/A

Detailed Description

This study is being conducted to evaluate hemodynamic performance using the new Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves. The study is intended to confirm the system's ability to increase venous blood flow over baseline as measured by blood velocity, time average mean velocity and total volume flow, in both the femoral and popliteal veins.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
19 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Design Validation Hemodynamic Study of New Kendall SCD SmartFlow Compression System With Cardinal Health Element Compression Sleeves
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single Arm

Baseline blood flow (hemodynamic) measurements will be obtained via ultrasound for all enrolled subjects. Following baseline measurements, compression will be applied and blood flow (hemodynamic) measurements will be repeated via ultrasound.

Device: Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)
External intermittent pneumatic compression (IPC) systems are applied to subject legs and comprise of a controller, associated tubing set and single patient use disposable leg sleeves. The disposable sleeves are latex free and contain air bladder(s) that are inflated by the controller to provide compression to the legs/feet. These devices are designed to increase venous blood flow in at risk patients in order to help prevent Venous ThromboEmbolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

Outcome Measures

Primary Outcome Measures

  1. Blood Velocity [baseline, +10 minutes]

    Blood Velocity (Baseline, Peak) will be assessed via ultrasound in the popliteal and femoral veins.

  2. Time Average Mean Velocity [baseline, +10 minutes]

    Time Average Mean Velocity (Baseline, Augmented) will be assessed via ultrasound in the popliteal and femoral veins.

Secondary Outcome Measures

  1. Total Volume Flow [baseline, +10 minutes]

    Total Volume Flow (Baseline, Augmented) will be assessed via ultrasound in the popliteal and femoral veins.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subject must be ≥18 years and ≤ 89 years of age.

  • Subject must be able to speak and read English.

  • Subject must have both legs fully intact (cannot be an amputee) with normal function.

  • Subject must be able to commit to the full study duration (approximately 1-2 hours of uninterrupted time).

  • Subject legs must fit into the provided knee length compression sleeves (<32").

  • Subject must give written informed consent.

Exclusion Criteria:
  • Subject is currently pregnant or breastfeeding.

  • Subject has a positive COVID history within the previous 6 months.

  • Subject presents with

    • local leg condition with which the sleeves would interfere such as dermatitis, vein ligation (immediate post-operative), gangrene, recent skin graft, or any other open wound
    • arteriosclerosis or other ischemic vascular diseases as indicated by absence of pedal pulses and/or history of intermittent claudication with positive pain response
    • edema of legs or pulmonary edema from congestive heart failure
    • deformity of the leg
    • current Deep Vein Thrombosis as identified during baseline clinical screening
    • recent or old Deep Vein Thrombosis as identified during baseline clinical screening
    • reflux in the superficial or deep veins
    • history of DVT/PE
    • known May-Thurner Syndrome
  • Subject who, in the opinion of the investigator, is not an appropriate candidate for the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jobst Vascular Institute Toledo Ohio United States 43606

Sponsors and Collaborators

  • Cardinal Health

Investigators

  • Principal Investigator: Fedor Lurie, Jobst Vascular Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cardinal Health
ClinicalTrials.gov Identifier:
NCT05945186
Other Study ID Numbers:
  • 450.30
First Posted:
Jul 14, 2023
Last Update Posted:
Jul 14, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Cardinal Health

Study Results

No Results Posted as of Jul 14, 2023